Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide Efficacy and Safety in First-line Acromegaly
NCT00171886Phase 4Completed
- Sponsor
- Novartis
- Start
- Jul 2002
- Primary completion
- May 2006
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of octreotide in acromegaly, sponsored by Novartis. Primary endpoints: Growth Hormone levels at 48 weeks, Insulin-like Growth Factor I levels at 48 weeks and 1 more. Started Jul 2002; status: completed.
02
Drugs
octreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT00171886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171886.